Castle Biosciences, Inc.
CSTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $332 | $220 | $137 | $94 |
| % Growth | 51.1% | 60.4% | 45.7% | – |
| Cost of Goods Sold | $60 | $45 | $32 | $16 |
| Gross Profit | $272 | $175 | $105 | $78 |
| % Margin | 81.9% | 79.5% | 76.6% | 83.2% |
| R&D Expenses | $52 | $54 | $45 | $30 |
| G&A Expenses | $77 | $66 | $56 | $0 |
| SG&A Expenses | $200 | $180 | $143 | $87 |
| Sales & Mktg Exp. | $123 | $114 | $87 | $0 |
| Other Operating Expenses | $11 | $9 | -$10 | $2 |
| Operating Expenses | $263 | $243 | $178 | $118 |
| Operating Income | $9 | -$68 | -$73 | -$40 |
| % Margin | 2.6% | -30.9% | -53.2% | -42.6% |
| Other Income/Exp. Net | $13 | $11 | $4 | $0 |
| Pre-Tax Income | $22 | -$57 | -$69 | -$40 |
| Tax Expense | $3 | $0 | -$2 | -$9 |
| Net Income | $18 | -$57 | -$67 | -$31 |
| % Margin | 5.5% | -26.1% | -49% | -33.3% |
| EPS | 0.66 | -2.14 | -2.58 | -1.24 |
| % Growth | 130.8% | 17.1% | -108.1% | – |
| EPS Diluted | 0.62 | -2.14 | -2.58 | -1.24 |
| Weighted Avg Shares Out | 28 | 27 | 26 | 25 |
| Weighted Avg Shares Out Dil | 29 | 27 | 26 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $11 | $4 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $16 | $12 | $11 | $3 |
| EBITDA | $38 | -$45 | -$58 | -$37 |
| % Margin | 11.5% | -20.5% | -42.6% | -38.9% |